Semaglutide activates one appetite pathway. Tirzepatide activates two. That single difference drives most of what sets them apart — from average results to how your provider may dose them.
The one-pathway vs. two-pathway difference
Semaglutide is a GLP-1 receptor agonist — it mimics the GLP-1 hormone your body releases after eating, which signals fullness and slows digestion. Tirzepatide does that too, but adds a second action on the GIP receptor, a separate hunger-and-metabolism pathway. Targeting both is why tirzepatide is sometimes described as a “dual agonist.”
Semaglutide
GLP-1 · compounded
- Targets one appetite pathway (GLP-1)
- Proven, well-studied weight loss
- A strong first step for most patients
- Weekly subcutaneous injection
Tirzepatide
GLP-1 + GIP · compounded
- Targets two pathways (GLP-1 + GIP)
- Greater average weight loss in trials
- Often chosen for maximum results
- Weekly subcutaneous injection
Average body-weight reduction in the landmark NEJM trials. Trials studied FDA-approved branded products; compounded medications are not FDA-approved. Individual results vary.
What about side effects?
Both medications share a similar side-effect profile because both act on the GLP-1 pathway. The most common effects are gastrointestinal — nausea, reduced appetite, and changes in digestion — and they’re usually most noticeable early and ease as your body adjusts. Because your medication is compounded on your provider’s prescription, your provider can adjust your starting dose and titration pace to help manage tolerability.
Your provider makes the call
Which medication is appropriate depends on your health history, current medications, and goals. AvataCore’s licensed providers review every intake and recommend the option that fits you — it isn’t a choice you have to make alone.
Can I switch between them later?
Many patients start on one and revisit with their provider over time. Any change is a clinical decision your provider makes based on your response and tolerability.
Is one safer than the other?
Both share a similar safety and side-effect profile. Neither compounded medication is FDA-approved, and eligibility for either is determined by a licensed provider after reviewing your medical history.
Do they cost the same at AvataCore?
Both start at $149 for your first 4 weeks (intro pricing). Your provider recommends the medication; pricing is transparent and shown before you check out.
See if you qualify
A licensed U.S. provider reviews every intake. No card required. Plans start at $149 for your first 4 weeks.
Take the 2-minute quiz →No card required · Same-day provider review · Cancel anytime
Keep reading
The Science
How GLP-1 Medications Actually Work
GLP-1 is a hormone your body already makes. Here’s how these medications extend its effect to make weight loss feel more natural — in plain language.
Getting Started
What to Expect in Your First Month
From qualifying to your first few weeks — a realistic, week-by-week look at starting a GLP-1 plan so there are no surprises.
Important: This content is for educational purposes only and is not medical advice. Compounded medications are NOT FDA-approved and are different from FDA-approved branded products such as Ozempic®, Wegovy®, Zepbound®, and Mounjaro®. They are prepared by licensed U.S. pharmacies under 503A regulation and have not been evaluated by the FDA for safety, efficacy, or quality. AvataCore is not affiliated with Novo Nordisk or Eli Lilly. Individual results vary. Eligibility for treatment is determined by a licensed provider. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly.